A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

PTC Therapeutics' Translarna loses EU conditional approval, but countries may allow continued use. PTC submitted four FDA ...

The benefits of naltrexone/bupropion (Mysimba) continue to outweigh its risks, despite ongoing uncertainty about long-term ...

The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the treatment of Alzheimer's disease.

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

Commonsense management measures can help keep arthritic horses comfortable and sound even in the coldest weather.

Eli Lilly CEO David Ricks reveals that developing a new drug costs around $4 billion before marketing. In an exclusive ...

The PMCPA has dug into the industry’s LinkedIn activities once again. | The PMCPA has dug into the industry’s LinkedIn ...

Compounded drugs, and particularly off-brand versions ... the spokesperson told Fierce Pharma Marketing, “We are referring to both compounded products and any products that are marketed like ...